Logo image of AMPE

AMPIO PHARMACEUTICALS INC (AMPE) Stock Fundamental Analysis

NYSEARCA:AMPE - NYSE Arca - US03209T3077 - Common Stock - Currency: USD

0.62  -0.09 (-12.91%)

Fundamental Rating

2

AMPE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. AMPE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AMPE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AMPE has reported negative net income.
AMPE had a negative operating cash flow in the past year.
AMPE had negative earnings in each of the past 5 years.
AMPE had a negative operating cash flow in each of the past 5 years.
AMPE Yearly Net Income VS EBIT VS OCF VS FCFAMPE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -150.51%, AMPE is doing worse than 88.27% of the companies in the same industry.
AMPE has a worse Return On Equity (-256.93%) than 77.04% of its industry peers.
Industry RankSector Rank
ROA -150.51%
ROE -256.93%
ROIC N/A
ROA(3y)-104.9%
ROA(5y)-96.3%
ROE(3y)-152.7%
ROE(5y)-152.1%
ROIC(3y)N/A
ROIC(5y)N/A
AMPE Yearly ROA, ROE, ROICAMPE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMPE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMPE Yearly Profit, Operating, Gross MarginsAMPE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for AMPE has been increased compared to 1 year ago.
AMPE has more shares outstanding than it did 5 years ago.
AMPE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMPE Yearly Shares OutstandingAMPE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
AMPE Yearly Total Debt VS Total AssetsAMPE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -63.84, we must say that AMPE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -63.84, AMPE is doing worse than 92.35% of the companies in the same industry.
There is no outstanding debt for AMPE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -63.84
ROIC/WACCN/A
WACCN/A
AMPE Yearly LT Debt VS Equity VS FCFAMPE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.41 indicates that AMPE has no problem at all paying its short term obligations.
With a Current ratio value of 2.41, AMPE perfoms like the industry average, outperforming 40.31% of the companies in the same industry.
AMPE has a Quick Ratio of 2.32. This indicates that AMPE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.32, AMPE is in line with its industry, outperforming 43.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.32
AMPE Yearly Current Assets VS Current LiabilitesAMPE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

AMPE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.86%, which is quite impressive.
EPS 1Y (TTM)48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMPE Yearly Revenue VS EstimatesAMPE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20K 40K 60K
AMPE Yearly EPS VS EstimatesAMPE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMPE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMPE Price Earnings VS Forward Price EarningsAMPE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMPE Per share dataAMPE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AMPE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPIO PHARMACEUTICALS INC

NYSEARCA:AMPE (4/12/2024, 8:04:00 PM)

0.62

-0.09 (-12.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25 2024-03-25/amc
Earnings (Next)05-06 2024-05-06/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners522.18%
Ins Owner Change0%
Market Cap514.60K
Analysts43.33
Price Target2.04 (229.03%)
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB 0.15
EV/EBITDA N/A
EPS(TTM)-11.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-10.32
FCFYN/A
OCF(TTM)-10.32
OCFYN/A
SpS0
BVpS4.05
TBVpS4.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -150.51%
ROE -256.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.9%
ROA(5y)-96.3%
ROE(3y)-152.7%
ROE(5y)-152.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.32
Altman-Z -63.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.91%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.47%
OCF growth 3YN/A
OCF growth 5YN/A